Therapixel

Executive Summary

Therapixel is a French AI software company that develops and commercializes MammoScreen, an FDA-cleared and CE-marked AI tool for breast cancer detection in mammograms. Founded in 2013, the company is headquartered in Valbonne, France, and focuses on improving radiologists' efficiency and diagnostic accuracy. With growing adoption of AI in radiology and increasing regulatory approvals, Therapixel is well-positioned to capture market share in the breast cancer screening and broader medical imaging market. The company's product has been clinically validated and is used in multiple healthcare institutions. Therapixel may pursue expansion into other imaging modalities (e.g., chest X-rays) and geographic markets, including deeper penetration in the US and Europe. The company is privately held with no disclosed fundraising or valuation data, but its strong IP and regulatory positioning make it a potential acquisition target for larger medtech or AI firms. Key risks include competition from established players (e.g., Aidoc, Zebra Medical Vision) and reliance on regulatory clearances and clinical adoption.

Upcoming Catalysts (preview)

• Q4 2026Expansion of MammoScreen to additional EU markets via CE marking extensions70% success
• Q2 2027FDA clearance for MammoScreen in lung cancer detection or chest imaging55% success
• Q3 2026Strategic partnership with a major imaging OEM or health system60% success